Human Pathology
Volume 41, Issue 6 , Pages 886-894 , June 2010

Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7—challenging the concept of dysplastic nevi as precursor lesions?

  • Kristen DeCarlo, MA

      Affiliations

    • Boston University School of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    • ,
  • Shi Yang, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    • ,
  • Andrew Emley, MA

      Affiliations

    • Division of Graduate Medical Sciences, Boston University School of Medicine, Boston, MA 02118, USA
    • ,
  • Narendra Wajapeyee, PhD

      Affiliations

    • Program in Gene Function and Expression, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • ,
  • Michael Green, MD, PhD

      Affiliations

    • Program in Gene Function and Expression, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • ,
  • Meera Mahalingam, MD, PhD, FRCPath

      Affiliations

    • Dermatopathology section, Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    • Corresponding Author InformationCorresponding author.

Received 23 October 2009 ,Revised 8 December 2009 ,Accepted 16 December 2009.

References 

  1. Briollais L, Chompret A, Guilloud-Bataille M, Bressac-de Paillerets B, Avril MF, Demenais F. Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. Int J Epidemiol. 2000;29:408–415
  2. Clark WH, Elder DE, Guerry DT, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15:1147–1165
  3. Hussein MR. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol. 2005;58:453–456
  4. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;18:1439–1444
  5. Salopek TG, Slade J, Marghoob AA, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol. 1995;33:441–450
  6. Kang S, Barnhill RL, Mihm MC, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol. 1994;130:999–1001
  7. Naeyaert JM, Brochez L. Dysplastic nevi. N Engl J Med. 2003;349:2233–2240
  8. Shors AR, White E, Argenyi Z, et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006;155:988–993
  9. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20
  10. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883–3885
  11. Loewe R, Dittler H, Fischer G, Fae I, Wolff K, Petzelbauer P. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol. 2004;123:733–736
  12. Turner DJ, Zirvi MA, Barany RE, Elenitsas R, Seykora J. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol. 2005;32:334–339
  13. Laud K, Kannengiesser C, Avril M, et al. BRAF as a melanoma susceptibility candidate gene?. Cancer Res. 2003;63:3061–3065
  14. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol. 2009;129:1483–1488
  15. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–348
  16. Uribe P, Andrade L, Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol. 2006;126:161–166
  17. Kuwata T, Kitagawa M, Kasuga T. Proliferative activity of primary cutaneous melanocytic tumours. Virchows Arch A Pathol Anat Histopathol. 1993;423:359–364
  18. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene. 2003;22:3063–3069
  19. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363–374
  20. Landi MT, Baccarelli A, Tarone RE, et al. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst. 2002;94:94–101
  21. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol. 1998;111:757–761
  22. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in non–sun-exposed sites. Clin Cancer Res. 2004;10:3444–3447
  23. Hussein MR. Genetic pathways to melanoma tumorigenesis. J Clin Pathol. 2004;57:797–801
  24. Hussein MR, Roggero E, Tuthill RJ, Wood GS, Sudilovsky O. Identification of novel deletion loci at 1p36 and 9p22-21 in melanocytic dysplastic and cutaneous malignant melanomas. Arch Dermatol. 2003;139:816–817
  25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  26. Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989;4:1363–1374
  27. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002;8:3468–3474
  28. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst. 2003;95:790–798
  29. Uribe P, Ignacia IW, Gonzalez S. BRAF mutation—a frequent event in benign, atypical and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003;25:365–370
  30. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160–1162
  31. Miller CJ, et al. Method of mutation analysis may contribute to discrepancies in reports of V599EBRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol. 2004;123:990–992
  32. Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res. 2005;15:401–407
  33. Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol. 2007;29:534–537
  34. Ichii-Nakato N, Takata M, Takayanagi S, et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol. 2006;126:2111–2118
  35. Whitwam T, VanBrocklin MW, Russo ME, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene. 2007;26:4563–4570
  36. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007;127:179–182
  37. Herlyn M, Satyamoorthy K. Acticated ras—yet another player in melanoma?. Am J Pathol. 1996;149:739–744
  38. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, Christophers E. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol. 1995;147:1615–1625
  39. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117–122
  40. Lebe B, Pabuccuoglu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15:160–164
  41. Wakefield DN, Krahl D, Wainer BH, Sellheyer K. Cytological atypia does not equal malignancy: an old but unappreciated truth. J Cutan Pathol. 2009;36:1014–1021
  42. Shukla VS, Hughes DC, Hughes LE, McCormick F, Padua RA. Ras mutations in human melanocytic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res. 1989;5:121–127
  43. Van't Veer LJ, Burgering BMT, Versteeg R, et al. N-ras mutation in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989;9:3114–3116
  44. Ball JN, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994;102:285–290

PII: S0046-8177(09)00453-5

doi: 10.1016/j.humpath.2009.12.002

Human Pathology
Volume 41, Issue 6 , Pages 886-894 , June 2010

Article Tools

* Image Usage & Resolution